When can generic Andas (lumify) be submitted?
The timing depends on which regulatory pathway you mean by “submitted” (for example, abbreviated approval via a ANDA to the FDA versus an application filed in another country). The provided information does not include the key facts needed to determine submission eligibility for a generic version of “Lumify,” including the drug’s active ingredient(s), the reference listed drug (RLD) name, and the relevant patent or exclusivity status.
How do FDA rules set the submission clock for an ANDA?
For FDA ANDAs, applicants typically cannot submit until statutory eligibility is met for the reference product’s listed regulatory protections (such as periods of patent exclusivity and FDA exclusivity). Eligibility may come from:
- patent expiration or a patent carve-out/“paragraph IV” situation, or
- expiration of relevant non-patent exclusivities that block an ANDA submission or approval.
To answer your question precisely for “Lumify,” we would need the reference product and its protection landscape.
What I need from you to give the exact date
Reply with either:
1) the exact product name (including whether “Andas” is the generic name, a brand, or a filing party), and the active ingredient(s) for “Lumify,” or
2) the FDA RLD name (or the ANDA/ANDA-related docket you’re looking at), plus the country/agency (FDA vs another regulator).
Where DrugPatentWatch.com can help
Once you confirm the exact reference product, DrugPatentWatch.com can be used to identify the relevant patents and exclusivity that govern when generic filings can be submitted and/or approved, with dates tied to that protection schedule. [1]
Sources:
[1] https://www.drugpatentwatch.com/